Gangliosides enhance neurite outgrowth in PC12 cells

Morphological modulation of cultured rat brain astroglial cells: antagonism by ganglioside GM1

Secondary cultures of neonatal rat astroglial cells, maintained in a serum-free, chemically defined medium were treated with several agents thought to activate cyclic AMP-synthesizing systems. Dibutyryl cyclic AMP (dBcAMP), forskolin and cholera toxin promoted, within 2 h, the near-complete conversion of 1-day-old (D1) astroglial cells from a flat, epithelioid morphology to a stellate (star-shaped) morphology. With all 3 agents, cell susceptibility to morphological change declined with culture age, 5-day-old cultures failing to respond altogether. D1 cultures, after 48 h of treatment, had reverted to the flat morphology. Gangliosides reported to stimulate adenylate cyclase were also tested, using purified GM1 X GM1 failed to stimulate the conversion to stellate morphologies. GM1, however, did affect these astroglial cells by causing a block or reversal of their morphological response to dBcAMP, forskolin or cholera toxin. The GM1 response was specific for the intact ganglioside molecule, asialo GM1 and sialic acid having no effect. Gangliosides GD1a, GD1b and GT1b were also active, being effective at ca. 4-fold lower concentrations. The response to GM1 appeared to involve a direct interaction with the astroglial cell, rather than influencing either substratum or medium components.

GM1 ganglioside counteracts selective neurotoxin-induced lesion of developing serotonin neurons in rat spinal cord

The effect of exogenous monosialoganglioside GM1 on neurotoxin-induced lesioning of bulbo-spinal serotonergic neurons of newborn rats was studied by means of biochemical and immunocytochemical techniques. 5,7-dihydroxytryptamine (5,7-HT, a selective serotonin neurotoxin) treatment of newborn rats caused a pronounced reduction of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in the thoracic and lumbar spinal cord, while an increase of 5-HT and 5-HIAA was found in the pons medulla. These biochemical alterations were regionally correlated with similar changes in 5-HT nerve terminal density analyzed by image analysis. GM1 administration (30 mg/kg for 4 consecutive days) antagonized the reduction of 5-HT and 5-HIAA levels induced by 5,7-HT treatment in the lumbar spinal cord of 2-month-old rats, as well as the decrease of 5-HT nerve terminal density in both thoracic and lumbar spinal cord of 1- and 2-month-old rats. A minor counteracting effect of GM1 was found in the pons medulla where the neurotoxin induced an increase of 5-HT and 5-HIAA levels. These data support the hypothesis that GM1 may have a preventing action on retrograde degenerative processes following chemical lesion and/or a growth-stimulating effect on injured 5-HT neurons.

GM1 ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selected culture conditions

Neurons from chick embryonic day 8 (E8) ciliary ganglia, E8 and E15 dorsal root ganglia, E8 forebrain, and from rat E18 hippocampus and striatum were cultured as monolayers in the presence or absence of GM1 ganglioside. All of the primary neurons tested were susceptible to an effect of GM1 on their neuritic outgrowth, resulting in a 2- to 3-fold stimulation over control, the recognition of which depended on selecting culture conditions appropriate to each case. The response of E8 ciliary ganglionic neurons required a serum-free medium containing ciliary neuronotrophic factor, and was most pronounced by 8 h at 3 X 10(-8) M GM1. The neuritic response by either E8 or E15 dorsal root ganglionic neurons required serum (greater than or equal to 0.3%), their appropriate neuronotrophic factor, and 100-fold higher GM1 concentrations (presumably reflecting the serum presence), with optimal response times of 12-24 h. For E8 chick forebrain and E18 rat central neurons, GM1 substantially increased the proportion of neurite-bearing neurons in a serum-free pyruvate-containing medium between 7 and 24 h, with an optimal GM1 concentration of 10(-7) M. In all cases, the response to GM1 was a time-related gain, i.e. an earlier onset of neuritic regeneration rather than permanent increase in the number of neurite-bearing neurons.

Quantitative analysis of myelin and axolemma particle distribution in C57BL/Ks diabetic mice and the effects of ganglioside treatment

By freeze-fracture technique we estimated myelin and axolemma intramembranous particle density in C57BL/Ks mice. A decrease in myelin particle content compared to controls is present in both 180 and 280 day old genetic diabetic mice. In addition, the axolemma of myelinated axons is affected in interparanodal regions while no modification was detected at nodal level. Such alterations of myelin membrane structure may also be responsible for the lower motor nerve conduction velocity (MNCV) observed in these diabetic mice; however this hypothesis cannot be taken into consideration for the reduction in MNCV at the early stage of the neuropathy (prior to 180 days of life). Therefore the structural changes of both myelin sheath and interparanodal axolemma as visualized by freeze-fracture are most likely related to late complications of the disease instead of being responsible for the changes in excitability. The low myelin and axolemma particle density of diabetic mice was found normal after 30 days' treatment with gangliosides. Such findings are in agreement with previous results on a significant effect of ganglioside treatment on MNCV and axonal area alterations in 180 and 280 day old genetic diabetic mice.

Ganglioside GM1 does not initiate, but enhances neurite regeneration of nerve growth factor-dependent sensory neurones

An enzyme-linked immunoadsorbent assay (ELISA) for neurofilament protein was utilised to quantify the effect of exogenous ganglioside on neurite regeneration in cultures of dorsal root ganglion neurones. In contrast to nerve growth factor (NGF), ganglioside GM1 (100 micrograms/ml) failed to support neuronal survival and neurite regeneration as quantified by the ELISA assay and confirmed by morphological criteria. However, the simultaneous presence of GM1 (100 micrograms/ml) and NGF (0.5-5 ng/ml) throughout a 5-day period of culture resulted in an enhancement of previously reported NGF-induced increases in the expression of neurofilament protein. Further, the addition of GM1 (0-200 micrograms/ml) at 48 h in vitro to cultures initially established in the presence of 5 ng/ml NGF substantially increased the subsequent expression of neurofilament protein, this response being both independent of and not potentiated by NGF. The results in the present system suggest that GM1 cannot initiate a programme of neurite regeneration; however, GM1 can enhance this process with the response being secondary to the effect of NGF.

Promoting functional plasticity in the damaged nervous system

Damage to the central and peripheral nervous system often produces lasting functional deficits. A major focus of neuroscience research has been to enhance functional restitution of the damaged nervous system and thereby produce recovery of behavioral or physiological processes. Promising procedures include surgical, physical, and chemical manipulations to reduce scar formation and minimize the disruption of support elements, administration of growth-stimulating substances, tissue grafts to bridge gaps in fiber pathways, and embryonic brain tissue grafts to provide new cells with the potential to generate fiber systems. Two elements are required for functional nervous system repair: (i) neurons with the capacity to extend processes must be present, and (ii) the regenerating neurites must find a continuous, unbroken pathway to appropriate targets through a supportive milieu.

The facilitating effect of gangliosides on the electrogenic (Na+/K+) pump and on the resistance of the membrane potential to hypoxia in neuromuscular preparation

The effects have been investigated of a mixture of gangliosides from beef brain cortex (GM1, GD1a, GD1b and GT1) either added to the bathing medium or injected intraperitoneally on muscle fibres and nerve terminals in mouse diaphragm. The electrogenic (Na+/K+) pump activity of muscle fibres enriched with sodium was increased by 38% after 2-h pretreatment with gangliosides (5 X 10(-8) mol X 1(-1]. Muscles from animals treated with gangliosides did not show the substantial depolarization of the resting membrane potential (RMP) in K+-free solution (6 h) shown by control muscles. Further, treatment with gangliosides slowed the changes in muscle fibre RMP and frequency of the miniature end-plate potentials in oxygen deprived muscles.

GM1 ganglioside does not stimulate reinnervation of the striatum by substantia nigra grafts

Ganglioside GM1 has been reported to promote reinnervation of the striatum by dopaminergic fibers following brain hemisection in the rat. In the present study, the possibility that chronic ganglioside GM1 (10 or 50 mg/kg day for 3 weeks) would promote reinnervation of the dopamine-denervated striatum by embryonic substantia nigra grafts was studied. No enhancement of the ingrowth of fibers from the grafts was observed. It is concluded that under this circumstance, the growth of catecholaminergic fibers is restricted by factors other than the availability of ganglioside GM1.

Quantitation of the in vitro neuroblastoma response to exogenous, purified gangliosides

Individual ganglioside species (possessing the gangliotetrose oligosaccharide) were purified from bovine brain gray matter and applied in varying concentrations to the culture medium of mouse neuroblastoma cells (N2A) in vitro. After 48 hr of incubation, the cells were stained, and the neuritogenic response quantitated with a video analysis system, employing a program to measure three parameters of neuroblastoma differentiation: neurites per cell (sprouting), neurite length (extension), and degree of neurite branching (arborization). All the individual gangliosides tested promoted neurite extension in a dose-dependent fashion. Asialogangliosides ("neutral" glycosphingolipids) were without effect, which suggests that sialic acid (N-acetylneuraminic acid) is necessary to elicit this cellular response. With increasing concentrations of GM1 (5 to 500 micrograms/ml), the average cellular neurite length increased significantly, whereas the number of neurites per cell decreased. With the trisialoganglioside GT1b, neurite length did not increase to the extent seen with GM1, but an increase in the number of neurites per cell (sprouting) and branch points per neurite (arborization) was observed. These results suggest that the in vitro neuronal response to exogenous gangliosides may combine specific responses to individual species making up the total.

GM1 ganglioside enhances regrowth of noradrenaline nerve terminals in rat cerebral cortex lesioned by the neurotoxin 6-hydroxydopamine

The effect of exogenous GM1 ganglioside on selectively noradrenaline-denervated rat cerebral cortex was investigated by measuring the spatial distribution of endogenous noradrenaline levels and by fluorescence histochemical analysis. A local noradrenaline denervation was produced by intracortical infusion of the selective catecholamine neurotoxin 6-hydroxydopamine for 3 or 7 days. The neurotoxin infusion caused an almost complete noradrenaline denervation in a restricted area around the infusion point as reflected by an almost complete long-term disappearance of noradrenaline nerve terminals and reduction of noradrenaline levels. There was with time a slow recovery of the levels, most likely related to a spontaneous noradrenaline nerve terminal regeneration. Post-treatment for 1 week with GM1 had very small effects on the 6-hydroxydopamine-induced reduction of the noradrenaline levels, while pretreatment with GM1 for 3 days before the neurotoxin infusion and continuing the GM1 administration for another 7-14 days significantly enhanced noradrenaline recovery, as observed both bio- and histochemically. GM1 had no effect on the 6-hydroxydopamine-induced noradrenaline depletion acutely, indicating that GM1 does not interfere with the direct neurotoxic actions of 6-hydroxydopamine. The present results thus indicate that exogenous GM1 enhances regrowth of noradrenaline nerve terminals which may be due to a regrowth stimulatory effect (regeneration/collateral sprouting) and/or related to protective actions of GM1 against retrograde degeneration of noradrenaline axons following the neurotoxin-induced lesion.

Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigro-striatal neurons after different types of lesion

The effect of GM1 ganglioside treatment on the recovery of biochemical and behavioral parameters which define the activity of nigro-striatal dopaminergic systems has been investigated in rats after different types of lesion. GM1 favours the recovery of tyrosine-hydroxylase activity, of the number and affinity of 3H-N-n-propyl-norapomorphine binding sites in the striatum of the lesioned side and reduces the apomorphine-induced rotational behavior after mechanical (i.e. unilateral hemitransection) but not after chemical (i.e. 6-OHDA injected in the substantia nigra) lesion. The source of regrowing dopaminergic nerve terminals in the striatum after hemitransection is mainly a response of intact remaining axons of the ipsilateral side. Moreover the contralateral nigro-striatal systems seems to play, through intrathalamic connections, an important role in regulating the GM1-induced increase of the tyrosine-hydroxylase activity.

Effect of GM1 ganglioside on neonatally neurotoxin induced degeneration of serotonin neurons in the rat brain

The effect of exogenous GM1 ganglioside on the 5,7-dihydroxytryptamine (5,7-HT; a selective serotonin neurotoxin) induced alteration of the postnatal development of central 5-hydroxytryptamine (5-HT; serotonin) neurons has been investigated using neuro-chemical and immunocytochemical techniques. Neonatal 5,7-HT (50 mg/kg s.c.) treatment is known to lead to a marked and a permanent degeneration of distant 5-HT nerve terminal projections (e.g. in cerebral cortex, hippocampus and spinal cord), while projections close to the 5-HT perikarya in the mesencephalon and pons-medulla increase their nerve density. These regional alterations are reflected by decreases and increases, respectively, of endogenous 5-HT, [3H]5-HT uptake in vitro and number of 5-HT nerve terminals demonstrated by immunocytochemistry. Treatment of newborn rats with GM1 (4 X 30 mg/kg s.c.; 24 h interval) had no significant effect on the postnatal development of 5-HT neurons. GM1 administration had furthermore no effect on the 5,7-HT induced alteration of the regional 5-HT levels and [3H]5-HT uptake in the cerebral cortex acutely, indicating that GM1 did not significantly interfere with the primary neurodegenerative actions of 5,7-HT. At the age of 1 month a clear counteracting effect of GM1 was observed, in particular of the 5,7-HT induced 5-HT denervations. The 5-HT levels in the frontal and occipital cortex were reduced to 25 and 20% of control after 5,7-HT alone, while these values were 70 and 40%, respectively, after 5,7-HT and GM1 treatment. A similar antagonizing effect of GM1 was found in the frontal cortex when measuring [3H]5-HT uptake. GM1 treatment also caused a minor reduction of the 5,7-HT induced increase of the 5-HT levels in striatum and mesencephalon. Quantitation of 5-HT nerve terminal density in sections processed for 5-HT immunocytochemistry using an automatic image analysis system showed markedly more nerve terminals in the frontal and occipital cortex after 5,7-HT + GM1 compared to 5,7-HT treatment alone. Minor counteracting effects of GM1 were noted in the hippocampus and spinal cord (thoracic-lumbar) as evaluated by chemical 5-HT assay, although substantial counteracting effects were observed locally in these areas by quantitative immunocytochemistry.(ABSTRACT TRUNCATED AT 400 WORDS)

Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat

The effect of GM1 ganglioside on the recovery of dopaminergic nigro-striatal neurons was studied in rats after unilateral hemitransection. GM1 treatment partially prevented the decrease of tyrosine hydroxylase (TH) activity caused by hemitransection in the substantia nigra ipsilateral to the lesion. Concomitantly a significant increase of TH-immunoreactivity in the substantia nigra was also detected. In particular, chronic treatment with GM1 prevented the disappearance of TH-positive cell bodies in the substantia nigra and induced the appearance of longer TH-positive dendrites with respect to the saline treatment. These data indicate that GM1 treatment maintains the number of dopaminergic cell bodies in the substantia nigra after hemitransection by protecting against retrograde neuronal degeneration.

Stimulation of nodal and terminal sprouting of mouse motor nerves by gangliosides

Treatment of mice with daily intraperitoneal gangliosides (50 mg/kg) enhanced both the number and mean length of nodal sprouts 4 days after partial denervation of the gluteus maximus muscle. Terminal sprouting in the soleus muscle 14 days after botulinum toxin paralysis was also enhanced by gangliosides, as assessed by zinc iodide-osmium tetroxide staining. Functional recovery from paralysis, assessed electrophysiologically, was simultaneously accelerated; this may have resulted from the enlarged terminal area, rather than reflecting an additional action of gangliosides upon synaptogenesis.

Biosynthesis of gangliosides in the developing chick embryo retina

Chick embryo retinas were cultured with [3H]glucosamine on each day between days 6 and 12 of development. The total labeling of gangliosides decreased from day 6 to day 12. The decrease was mostly due to the decrease in the labeling of disialosyllactosylceramide (GD3), which diminished to less than 2%, while the labeling of the disialoganglioside GD1a decreased to about 30%. Labeling of endogenous gangliosides by incubating retina homogenates with CMP-[3H]N-acetylneuraminic acid, in addition to showing a decrease in the labeling of GD3, showed a twofold increase in the labeling of GD1a. The changes in the pattern of labeling correlated with the decrease of both the incorporation of [3H]thymidine into DNA and the activity of CMP-NeuAc:GM3 sialosyltransferase and with the increase of both the activities of UDP-Ga1NAc:GM3 N-acetylgalactosaminyltransferase and choline acetyltransferase. The results suggest that the shift in the pattern of labeling of gangliosides occurs in association with the transition from the proliferative to the nonproliferative state of neuronal cells. Retinas at each age cultured with [3H]glucosamine for 22 hr maintain the radioactivity in gangliosides for at least 4 additional days in culture. This indicates that within this developmental interval there is not a period characterized by having a high turnover rate of gangliosides.

The functional recovery of damaged brain: the effect of GM1 monosialoganglioside

In the present study the topology and the biochemical mechanisms underlying the functional recovery of the dopaminergic nigrostriatal system is further analyzed. Rats with unilateral hemitransection were treated with 30 mg/kg GM1 monosialoganglioside or with its internal ester derivative for different periods of time. GM1 enhances 3H-dopamine uptake in striatal synaptosomes of the lesioned side, and the enhancement of dopamine uptake precedes that of striatal tyrosine hydroxylase activity. The above biochemical effects are accompanied by changes in behavioral- and electrophysiological-related parameters. The effect of GM1 on striatal tyrosine hydroxylase of the lesioned side disappears when the ascending dopaminergic fibers are extensively lesioned. This suggests that the source of regrowing dopaminergic nerve terminals in the striatum of partially lesioned rats resides mainly in the intact axons remaining in the ipsilateral side. When GM1 is injected into partially lesioned rats kept in darkness, no effect on tyrosine hydroxylase activity is observed. This indicates that the mechanism through which GM1 acts involves a normal light-dark cycle.

Gangliosides minimize behavioral deficits and enhance structural repair after brain injury

Injections of GM1-gangliosides (30 mg/kg, i.p.) in adult rats were shown to reduce behavioral deficits after brain lesions. This was observed (1) after bilateral electrolytic lesions of the caudate nucleus in a learning task involving negative reinforcement; (2) following aspiration lesions of the mediofrontal cortex in a learning task involving positive reinforcement; and (3) when rotational behavior was assessed after amphetamine or apomorphine injections in animals with partial hemitransections of the nigro-striato-nigral fibers. A detailed anatomical analysis of the latter study, using a retrograde tract-tracing dye wheat germ agglutinin-horseradish peroxidase (WGA-HRP), provided evidence for ganglioside-stimulated, neuronal reorganization of connections to the caudate nucleus. Our findings support the notion that gangliosides reduce behavioral deficits following brain injury by preventing secondary neuronal degeneration and/or enhancing structural reorganization of remaining afferents, rather than by influencing denervation supersensitivity.

Can functional reorganization of area 17 following monocular deprivation be modified by GM1 internal ester treatment?

It has been extensively reported that monocular exposure early in life leads to profound alterations in visual cortical areas, where the majority of cells become responsive only to the stimulation of the normal eye. We have investigated a possible effect of the monosialoganglioside internal ester, termed AGF2, on the neuronal cortical plasticity of the kitten's visual cortex following monocular deprivation. Results indicate that in monocularly deprived kittens treated with ganglioside the ocular dominance shift in favor of the normal eye is partially prevented.

Biology of gangliosides: neuritogenic and neuronotrophic properties

Research on the biologic function of gangliosides has accelerated in recent years following discovery of their pronounced effects when administered exogenously to neurons in culture and in vivo. These effects are of two principal types: 1) neuronotrophic, concerned primarily with survival and maintenance of the neuron, and 2) neuritogenic, involving significant increase in the number, length, and/or branching of neuronal processes. Such neurite-promoting activity has been observed in primary cultures of neurons from brain and ganglia as well as transformed lines of neuronal origin. These phenomena may be related to the remarkable growth of aberrant secondary neurites, often accompanied by synaptogenesis, observed in the gangliosidoses. Several in vivo studies have shown exogenously administered gangliosides to aid nervous system repair in both the CNS and PNS, although it is not clear in some cases whether the observed effects should be attributed to neuronotrophic or neuritogenic effects (or both). This article attempts to briefly review the principal developments that have occurred in this area of ganglioside research over the past several years. It also presents for consideration some of the tentative hypotheses put forward concerning mechanism of action.

Gangliosides' dual mode of action: a working hypothesis

Using in vitro preparations, we have tested the hypothesis that gangliosides, and more specifically GM1, may prevent progressive neural damage following a trauma by means of complex intracellular mechanisms that might be triggered originally by ganglioside interaction with neuronal membranes. We have recently shown that 2-hr ganglioside incubation in vitro stimulates the membrane Na/K pump in neuromuscular preparations. However, 5-6-hr incubation or in vivo treatment for 3 days with a daily injection of gangliosides at a dose of 1 or 10 mg/kg prevents the depolarization that normally occurs after several hours of exposure to K+-free solutions. In such undepolarized muscles, the electrogenic Na+/K+ pump does not seem to be activated. Hippocampal slices subjected to hypoxia undergo depolarization, which is reversed after oxygen readmission. The recovery phase is characterized by a huge hyperpolarization, probably reflecting electrogenic pump activity. In control preparations the depolarization occurs after 3.15 +/- 0.4 min and has a value of 48.7 +/- 5.7 mV; GM1 treatment for at least 4-5 hr increases the latency to 7.3 +/- 2.3 min, and the depolarization is reduced to 31.8 +/- 4.5 mV. This protective effect is accompanied by a reduced hyperpolarization in treated preparations. The ionic studies performed on neuromuscular preparations indicate that the protective effect may not be solely dependent on K+ leakage; however, the experiments are not conclusive and must be repeated with more direct methods. The results obtained indicate a dual mode of action for gangliosides. The early one seems characterized by membrane-enzyme activation, perhaps in relationship to their incorporation in the membrane, which could be compatible with previously described effects, such as enhancement of neuronal sprouting and neuritogenesis. The late one, occurring 4-5 hr after ganglioside addition in vitro, might reflect intracellular events and be compatible with the protective action exhibited by gangliosides against neural damage.

Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons lesioned by selective neurotoxins

The effect of exogenous GM1 ganglioside on selective neurotoxin-induced lesions of serotonin (5-HT) and noradrenaline (NA) neurons in both the central and peripheral nervous systems has been investigated in developing and adult rats and mice by employing neuro- and histochemical techniques. 5,7-Dihydroxytryptamine (5,7-HT) was used to lesion 5-HT neurons, and 6-hydroxydopamine (6-OH-DA) was used to lesion NA neurons. In most lesion models investigated the neurotoxin causes primarily an axonal nerve terminal damage without notably affecting the perikarya. There was no evidence indicating that GM1 interferes with the primary and direct neurodegenerative actions of 5,7-HT or 6-OH-DA on 5-HT and NA nerve terminals, respectively. In all lesion models GM1 had in the chronic stage a counteracting effect on the neurotoxin-induced nerve terminal lesion or enhanced regrowth. The present results are compatible with the view that GM1 has a regrowth-stimulating effect and/or protective actions against secondary retrograde degeneration following the initial nerve terminal lesion induced by the neurotoxin.

Dorsal root ganglia and nerve growth factor: a model for understanding the mechanism of GM1 effects on neuronal repair

The experimental strategy of adding monosialoganglioside GM1 to a culture medium of fetal chick dorsal root ganglia (DRG) was utilized as a model system in which to examine the potential role of GM1 in modulation of neuronal cell responsiveness to nerve growth factor (NGF). Data indicate that the addition of GM1 to DRG explants or to DRG dissociated neuronal cells in culture enhances NGF-induced neurite outgrowth, neurite complexity, and neuronal cell survival following NGF withdrawal. The GM1 molecule apparently facilitates the acquisition or maintenance of the NGF-induced specific neuronal properties. Results are consistent with the hypothesis that the presence of GM1 molecules on the neuronal cell surface, either endogenous or following stable insertion of exogenous molecules, plays a prominent role in the modulation of functional neuronal cell behavior in response to varying neuronotrophic signals. This may prove to be relevant for the comprehension of GM1 effects on the facilitation of central nervous system repair processes.

Interaction of GM1 ganglioside with PC12 pheochromocytoma cells: serum- and NGF-dependent effects on neuritic growth (and proliferation)

The effects of ganglioside GM1 on proliferation and neuritic growth of PC12 pheochromocytoma cells were studied in the presence and absence of nerve growth factor (NGF). In the absence of NGF, but not in its presence, a decrease in the total number of PC12 cells was first observed after 4-6 days of culture with 10(-6) M GM1 in 0.1% fetal calf serum, and with 10(-3) M GM1 on 10% serum. NGF, with or without GM1, limits cell growth to the first 4-6 days. GM1 enhanced neuritic recruitment with serum concentrations of 0.3% or more. Optimal neurite response varied from 10(-6) M GM1 with 0.3% serum to 10(-4) M GM1 with 10% serum. The influence of GM1 on neurites became more pronounced with increasing serum concentrations, becoming maximal with 1% or greater serum. Serum exhibited a concentration-dependent inhibitory influence (lag) on NGF-induced neuritic recruitment, which was abolished by GM1. Rates of neuritic recruitment following the lag were unaffected by GM1, while showing an inverse correlation with serum concentrations of 0.1-0.5%. Serum may delay the NGF-induced neuritic recruitment of PC12 cells by two independent mechanisms. These results suggest that GM1, in some manner, prevents the serum-induced delay in the onset of neuritic recruitment, rather than stimulating the rate at which it precedes.

Effects of ganglioside treatments on lesion-induced behavioral impairments and sprouting in the CNS

Recent findings suggest that exogenous gangliosides improve recovery of a learned behavior (alternation in a T-maze) which is thought to be related to sprouting after lesions of the entorhinal cortex. In the present investigation, we studied an unlearned behavior (the open-field hyperactivity resulting from bilateral entorhinal lesions) to evaluate whether ganglioside treatments reduce the severity of initial postlesion impairments or improve recovery. We also examined whether the treatments enhance the sprouting of septodenate fibers which parallels the recovery of open-field activity. The typical behavioral changes induced by bilateral entorhinal lesions include hyperactivity, reduced habituation of activity, and a gradual time-dependent return toward control levels. We found that rats treated with total brain gangliosides (30 mg/kg) showed a smaller lesion-induced increase, consistently lower levels, and greater within-session habituation of activity than did saline-treated counterparts. Control rats treated with gangliosides did not exhibit a reduction in activity, suggesting that the effect was on lesion-induced hyperactivity rather than on activity, per se. Ganglioside-treated rats showed a slight, but consistently smaller lesion-induced sprouting response by the septodentate pathway than did untreated counterparts at all postlesion intervals examined (3, 5, 7, and 10 days). The present findings indicate that ganglioside treatments reduce the severity of the initial behavioral effects after entorhinal lesions without enhancing the sprouting by septodentate fibers.

Ganglioside treatment of genetic and alloxan-induced diabetic neuropathy

Peripheral neuropathy is a common complication of diabetes. Using the mutant diabetic mouse C57BL/ks (db/db) and alloxan-treated rats, 30 days after intoxication, we investigated development and treatment with gangliosides of such a disease. The db/db mouse develops a neuropathy characterized by a loss in conduction velocity shown as early as 80-90 days after birth and maintained throughout life. At later stages (5-6 months of age) there is a drop in slow transport and myelin particle density. These changes are correlated by a lack of response to insulin treatment, which, prior to this stage, is capable of improving nerve conduction velocity (NCV). On the other hand gangliosides became effective, improving NCV, myelin particle density and sensory perception (auditory deficit) at 5 months of age in the db/db mouse. We presume that this differential neuronal response to insulin and gangliosides indicates a change of the neuropathy from a metabolic stage to neuronal. Alloxan induced diabetic neuropathy is treatable with gangliosides even 30 days after intoxication.

Reduction of cerebral edema with GM1 ganglioside

Administration of exogenous gangliosides has been reported to accelerate neurite outgrowth in vitro, and to enhance peripheral nerve regeneration and central nervous system recovery subsequent to damage. After injury, facilitation of CNS recovery with GM1 ganglioside treatment has been postulated to be due to enhanced neuronal regeneration. Since maximal recovery is achieved when experimental animals are treated before injury with GM1 ganglioside, an alternative or parallel mechanism is that gangliosides are "protecting" the CNS by limiting the extent of damage (ie, cell loss, process degeneration, membrane disruption). This may be due to a reduction in the edema subsequent to injury. In this study, rats were treated for 2 days with 20 mg/kg/day of GM1 ganglioside. On the third day they were subjected to a unilateral lesion (mechanical) of one cerebral hemisphere and given another 20 mg/kg of GM1. On the fourth day brains were removed for analysis of edema resulting from the injury. In treated animals there was a significant reduction in edema as measured either in the entire injured hemisphere (23%) or in the area of injury (33%). No effect was seen outside the damaged area. Since exogenous gangliosides can spontaneously "insert" into membranes, it is postulated that the effect of the GM1 may be due to alterations of membrane processes (eg, lipid hydrolysis, phospholipase activation, levels and membrane action of arachidonic acid, ionic permeation) that are characteristic of edema.

Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial

Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. the treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p less than 0.03) in patients of protocol I, MCV o ulnar nerve (p less than 0.002) and SCV of median nerve (p less than 0.06) in patients of protocol II. Furthermore, 22 subjects of protocol II showed a 'drug preference' while 10 preferred placebo and 9 had no preference. In conclusion, ganglioside treatment seems to have a positive effect on diabetic peripheral neuropathy, improving both some symptoms and some electrophysiological parameters.